TGM2-P2RX7 loop promotes gemcitabine resistance in pancreatic cancer by modulating glutamine metabolism and mitophagy

Ke Ye, Shuhua Zhou, Xuejun Gong, Zhongcheng Zhu, Moyan Xiao, Shuai Liang · 2025

Read TGM2-P2RX7 loop promotes gemcitabine resistance in pancreatic cancer by modulating glutamine metabolism and mitophagy by Ke Ye, Shuhua Zhou, Xuejun Gong, Zhongcheng Zhu, Moyan Xiao, Shuai Liang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12780038.txt.

Description

Ke Ye and co-authors study why some pancreatic tumors stop responding to a common drug called gemcitabine. Their 2025 paper focuses on two proteins, TGM2 and P2RX7, that were found at high levels in drug-resistant cancer cells and in tissue from patients whose treatment failed. The team tested cells in the lab and in animals.

Lowering TGM2 slowed the growth of resistant cells by changing how they use glutamine, a key fuel. The two proteins form a loop, each raising the other, and together they drive fuel use and a cell-cleaning process that helps the cancer resist the drug. The authors suggest that breaking this loop could be a new way to treat this cancer.

Catalog record

CREATORKe Ye, Shuhua Zhou, Xuejun Gong, Zhongcheng Zhu, Moyan Xiao, Shuai Liang
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE66 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12780038

Browse the full library · About the Tower of Babel